 
 
Comparison of the ToFscan and TetraGraph  
during Recovery of Neuromuscular Function in  
the Post Anesthesia Care Unit  
 
 
 [STUDY_ID_REMOVED]  
 
 
11/O ct/19 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 1 of 30 
J. Ross Renew , MD   CONFIDENTIAL   
 
Comparison  of the ToFscan  and TetraGraph  
during  Recovery  of Neuromuscular Function in 
the Post Anesthesia  Care Unit 
 
 
Regulatory Sponsor  
Principal Investigator: J. Ross Renew , MD  
Funding Sponsor:  
 Protocol Number:  Mayo Clinic  
 18-011298 
Study Product:  TetraGraph  
List of Participating Centers:   
1. Site Principal Investigator: Bé la Fülesdi , MD 
University of Debrecen  
Department of Anesthesiology and Intensive Care 94 Nagyerdei krt. 4031 Debrecen, Hungary  
2. Site Principal Investigator: Glenn Murphy, MD NorthShore University HealthSystem Department of Anesthesia, Critical Care, and & Pain Medicine  
2650 Ridge Ave Evanston, IL 60201 
  Initial version:  [07Nov2018] Version (1 .0)  
Revision: [20Nov2018] Version (1.1) Revision: [08Jan2019] Version (1.2) Revision : [26Apr2019] Version (2.0) 
Revision: [6Jun 2019] Version (2.1) 
Revision: [11Oct2019] Version (3.0) 
 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 2 of 30 
J. Ross Renew , MD   CONFIDENTIAL   
Table of Contents 
 
 PROTOCOL APPROVAL FORM  ........................................................................................................ 4  1
 LIST OF ABBREVIATION S ................................................................................................................ 5  2
 STUDY SUMMARY ............................................................................................................................. 6  3
 INTRODUCTION  ................................................................................................................................. 7  4
4.1 ABSTRACT  .......................................................................................................................................... 7  
4.2 BACKGROUND  .................................................................................................................................... 7  
4.3 RISKS AND BENEFITS  ......................................................................................................................... 10 
 STUDY OBJECTIVES  ........................................................................................................................ 10 5
 STUDY DESIGN  ................................................................................................................................. 10 6
6.1 GENERAL DESCRIPTION  ..................................................................................................................... 10 
6.2 NUMBER OF SUBJECTS  ....................................................................................................................... 10 
6.3 DURATION OF PARTICIPATION  ............................................................................................................ 10 
6.4 PRIMARY STUDY ENDPOINTS  .............................................................................................................. 11 
6.5 SECONDARY STUDY ENDPOINTS  ......................................................................................................... 11 
6.6 IDENTIFICATION OF SOURCE DATA ...................................................................................................... 11 
 SUBJECT SELECTION ENROLLMENT AND WITHDRA WAL  ...................................................... 12 7
7.1 INCLUSION CRITERIA  ......................................................................................................................... 12 
7.2 EXCLUSION CRITERIA  ........................................................................................................................ 12 
7.3 SUBJECT RECRUITMENT , ENROLLMENT AND SCREENING  ....................................................................... 12 
7.4 EARLY WITHDRAWAL OF SUBJECTS  .................................................................................................... 12 
7.4.1  When and How to Withdraw Subjects  ........................................................................................ 12 
7.4.2  Data Collection and Follow -up for Withdrawn Subjects  .............................................................. 13 
 STUDY DEVICE  ................................................................................................................................ 13 8
8.1 DESCRIPTION  .................................................................................................................................... 13 
8.2 METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS  ................................................................ 13 
8.3 MASKING /BLINDING OF STUDY ........................................................................................................... 13 
 STUDY PROCEDURES  ...................................................................................................................... 13 9
9.1 VISIT 1 (SCREENING AND ENROLLMENT UP TO THE DAY OF SURGERY ) .................................................... 14 
9.2 VISIT 2 (RANDOMIZATION AND TREATMENT – DAY OF SURGERY ) ........................................................... 14 
9.3 SCHEDULE OF EVENTS  ....................................................................................................................... 15 
 STATISTICAL PLAN  ......................................................................................................................... 15 10
10.1 SAMPLE SIZE DETERMINATION  ....................................................................................................... 15 
10.2 STATISTICAL METHODS  ................................................................................................ ................. 16 
10.3 SUBJECT POPULATION (S) FOR ANALYSIS  ......................................................................................... 16 
 SAFETY AND ADVERSE E VENTS  ................................................................................................... 17 11
11.1 DEFINITIONS  ................................................................................................................................ 17 
11.1.1  Unanticipated Problems Involving Risk to Subjects or Others (UPIRTSO)  ...................... 17 
11.1.2  Adverse Event  ................................................................................................................... 17 
11.1.3  Serious Adverse Event  ..................................................................................................... 17 
11.1.4  Adverse Event Reporting Period  ....................................................................................... 18 
11.1.5  Preexisting Condition  ........................................................................................................ 18 
11.1.6  Post-study Adverse Event  ................................................................................................. 18 
11.1.7  Hospitalization, Prolonged Hospitalization or Surgery  ...................................................... 18 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 3 of 30 
J. Ross Renew , MD   CONFIDENTIAL  11.2 RECORDING OF ADVERSE EVENTS  .................................................................................................. 18 
11.3 REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  ...................................... 19 
11.3.1  Sponsor -Investigator reporting: notifying the Mayo IRB  ......................................................... 19 
11.4 MEDICAL MONITORING  ................................................................................................................. 20 
 DATA HANDLING AND RECORD KEEPING  .................................................................................. 21 12
12.1 CONFIDENTIALITY  ........................................................................................................................ 21 
12.2 SOURCE DOCUME NTS .................................................................................................................... 21 
12.3 CASE REPORT FORMS  .................................................................................................................... 21 
12.4 DATA MANAGEMENT  .................................................................................................................... 21 
12.5 DATA PROCESSING  ........................................................................................................................ 22 
12.6 DATA SECURITY AND CONFIDENTIALITY  ......................................................................................... 22 
12.7 DATA QUALITY ASSURANCE  .......................................................................................................... 22 
12.8 DATA CLARIFICATION PROCESS  ..................................................................................................... 22 
12.9 RECORDS RETENTION  .................................................................................................................... 23 
 STUDY MONITORING, AUDITING, AND INSPECTI NG ................................................................ 23 13
13.1 STUDY MONITORING PLAN ............................................................................................................ 23 
13.2 AUDITING AND INSPECTING  ........................................................................................................... 23 
 ETHICAL CONSIDERATIO NS ......................................................................................................... 23 14
 STUDY FINANCES  ............................................................................................................................ 24 15
15.1 FUNDING SOURCE  ......................................................................................................................... 24 
15.2 CONFLICT OF INTEREST  ................................................................................................................. 24 
15.3 SUBJECT STIPENDS OR PAYMENTS  .................................................................................................. 24 
 PUBLICATION PLAN  ....................................................................................................................... 24 16
 REFERENCES  ................................................................................................................................... 24 17
 LIST OF IN -TEXT TABLE S .............................................................................................................. 26 18
18.1 SCHEDULE OF EVENTS  ................................................................................................................... 26 
18.2 INTRAOPERATIVE DATA ................................................................................................................. 26 
18.3 PACU  DATA  ................................................................................................................................. 27 
 LIST OF IN -TEXT FIGURES ............................................................................................................. 29 19
19.1 TETRA GRAPH  ............................................................................................................................... 29 
19.2 TOFSCAN  ..................................................................................................................................... 29 
19.3 VNRS  ......................................................................................................................................... 30 
 
   
  
 
 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 5 of 30 
J. Ross Renew , MD   CONFIDENTIAL   
 List of Abbreviations  2
 
 
AE Adverse Event/Adverse Experience  
AMG  Acceleromyography  
CE Conformite Europeene  
CFR  Code of Federal Regulations  
cMAPs  Compound Muscle Action Potentials  
CRF  Case Report Form  
CTSA  Center for Translational Science Activities  
DSMB  Data and Safety Monitoring Board  
EMG  Electromyography  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HER  Electronic Health Record  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
IRB Institutional Review Board  
KMG  Kinemyography  
MMG  Mechanomyography  
NMBA  Neuromuscular Blocking Agent  
Non-UPIRTSO  Non-Unanticipated Problems Involving Risk to Subjects or 
Others  
PACU  Post Anesthesia Care Unit  
PHI Protected Health Information  
PI Principal Investigator  
SAE  Serious Adverse Event/Serious Adverse Experience  
SOP Standard Operating Procedure  
TOF  Train -of-four 
UPIRTSO  Unanticipated Problems Involving Risk to Subjects or Others  
VNRS  Verb al Numeric Rating Scale  
     
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 6 of 30 
J. Ross Renew , MD   CONFIDENTIAL   Study Summary  3
Title  Comparison of the ToFscan and TetraGraph during Recovery of 
Neuromuscular Function in the Post Anesthesia Care Unit  
Running Title  ToFscan vs TetraGraph  
Phase N/A 
Methodology Randomized, Open -Label  
 
Overall Study 
Duration 6 months 
Subject Participation Duration Less than 1 hour 
Single or Multi- Site  Multicenter International  
Objectives  The primary aim of this study is to  assess the agreement and 
repeatability between TOF values obtained from ToFscan and 
TetraGraph  
Number of Subjects 120 (40 per site) 
Diagnosis and Main Inclusion Criteria  Patients undergoing an elective surgery and requiring administration of 
NMBA intrao peratively  
Study Device  TetraGraph  
 
Duration of Administration  Single stimulation of ulnar nerve repeated at specific intervals as outlined in the Study Procedures ( Section 6.2
) 
Reference therapy  ToFscan  
Statistical Methodology This pilot study is meant to be descriptive and it aims to collect basic data for future larger study  
  
 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 7 of 30 
J. Ross Renew , MD   CONFIDENTIAL   Introduction  4
 
This document is a protocol for a human research study. This study will be carried out in accordance with the applicable U nited States  government regulations and Mayo Clinic  research 
policies and procedures.   
4.1 Abstract  
 
Residual neuromuscular blockade is a common occurrence in the post- anesthesia care unit 
(PACU) when neuromuscular blocking agents (NMBAs) have been used in the operating room.  
The only method of reliably detecting residual neuromuscular blockade is through the use of quantitative neuromuscular monitors.   Unfortunately, several barriers exist that have prevented the widespread application  of these devices.  For instance, there is a paucity of quantitative 
neuromuscular monitors commercially available.  Also, two modalities of quantitative monitoring, kinemyography and acceleromyography, rely on movement of the muscles of interest, a characteristic frequently compromised during patient positioning for surgical procedures or in uncooperative awake patients in the PACU.  Additionally, many clinicians are unfamiliar with these quantitative monitors, and incorporating them into their practice ca n 
represent an undesirable educational burden.  The aim of this investigation is to compare the performance of two quantitative monitors utilized on post- anesthesia recovering patients.  The 
ToFscan (Draeger Medical Inc., Telford, PA) represents one of the few standalone acceleromyography (AMG) -based quantitative monitors available for routine clinical use in the 
United States.  The TetraGraph (Senzime AB, Uppsala, Sweden) is a standalone electromyography (EMG) -based quantitative monitor that recently received Conformité 
Européene (CE) approval.  While both of these quantitative monitors can be utilized to guide intraoperative NMBA re-dosing and confirm recovery, they provide their objective data via drastically different techniques.  AMG, based on Newton’s Second law which describes force being proportional to acceleration, measures acceleration of the thumb and requires its unobstructed movement.  As such, performing AMG in awake, uncooperative patients can yield inaccurate results because of unwanted patient movement.  Alternatively, EMG measures electrical activity within the muscle following peripheral nerve stimulation, and is unaffected by involuntary patient motion.  We plan to compare measurements with these two devices throughout various stages of neuromuscular recovery in the PACU end compare the usefulness of these devices in this vulnerable patient population.  
4.2 Background 
 
Postoperative residual  weakness  from  neuromuscular blockade continues to  be a common 
problem in  the post- anesthesia care unit (PACU).  Despite  the routine use of  reversal  agents, a 
significant number of patients  continue to  arrive  in the PACU with  objective evidence of residual  
neuromuscular blockade (Naguib, Kopman, and Ensor 2007; Cammu  et al. 2006).  While  not 
every  patient  with  residual  weakness  develops a postoperative complication,  many  can develop  
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 8 of 30 
J. Ross Renew , MD   CONFIDENTIAL  avoidable critical respiratory  events  (Murphy  et al. 2008; Berg  et al. 1997).  Furthermore,  special  
populations such  as the elderly,  are at particular  risk for developing complications related  to 
postoperative residual  weakness  (Murphy  et al. 2015).  The  use of quantitative  monitoring has  
been  demonstrated  to reliably  reduce the incidence  of postoperative residual  weakness  and the 
ensuing complicatio ns (Todd, Hindman, and  King  2014; Todd and  Hindman 2015; Murphy et  al. 
2011).  With  an abundance of literature  supporting the use of objective neuromuscular monitors, 
a panel  of experts  recently  recommended  the universal adoption of such  devices  whenever  
NMBA  are utilized  (Naguib et  al. 2018).   
Quantitative neuromuscular monitoring devices objectively measure residual weakness and 
display the results numerically.  This is  traditionally accomplished by performing a train -of-four 
(TOF) stimulation at the ulnar nerve and measuring the response of the adductor pollicis muscle.  The degree of muscle weakness is determined by calculating the TOF ratio, which consists of the ratio of the fourth muscle contraction to the first.  Adequate recovery that excludes clinically 
significant weakness from neuromuscular blockade is defined as a TOF ratio ≥ 0.9, a measurement that can be determined reliably only with a quantitative monitor (Sundman et al. 2000; Eriksson et al. 1997).  Although evidence strongly suggests objective monitors should be used perioperatively whenever NM BAs are administered, these devices can be expensive and 
require additional training.  Many clinicians default to the antiquated practice of utilizing qualitative (subjective) neuromuscular stimulating units such as a peripheral nerve stimulator (PNS) (Grayling and Sweeney 2007; Naguib et al. 2010). 
There are several  types  of quantitative  neuromuscular monitors.  These devices  can be 
incorporated into  the anesthesia workstation, allowing  data to  be seamles sly integrated  into the 
electronic medical  record.   Unfortunately, this  setup  can preclude using these monitors in  the 
PACU as  portability  is sacrificed.   In contrast,  other monitors exist  as standalone, portable (hand-
held) units.   
Aside  from  portability , objective  monitors can  further  be categorized  based  on the modality  
utilized  to measure responses.  Mechanomyography  (MMG)  measures  the force of contraction of 
the adductor pollicis  (thumb) muscle  following ulnar nerve stimulation  and has served  as the 
traditional “ gold-standard ”.  Mechanom
 yographic responses are  precise and reproducible, 
however the setup  is cumbersome and  the lack  of commercially  available devices  has relegated  
MMG  to strictly  research  purposes. Acceleromyography  (AMG) measures  accelerat ion of a 
muscle  group (typically  the thumb) in  response to  stimulation  (typically  the ulnar nerve).  This  
technique is  similar  to MMG,  but instead  of measuring  the force  of muscle  contraction, an  
accelerometer  fixed  to the thumb measures  the acceleration  of the thumb in  response to  ulnar 
nerve stimulation.   Based  on Newton’s  Second  law that states  force  is proportional to  
acceleration,  the measured  acceleration  is correlated  with  the force  of contraction  in the clinical  
setting.   There are  currently  two standalone AMG -based  monitors available for clinical use:  the 
STIMPOD  (Xavant  Technologies,  Pretoria,  South Africa) and  the ToFscan  (Draeger Medical  
Inc., Telford,  PA).   These devices  represent  improvements in  AMG technology over its  
predecessor,  the TOF -Watch  (Schering -Plough Corp., Kenilworth, NJ,  USA)  as they utilize  three 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 9 of 30 
J. Ross Renew , MD   CONFIDENTIAL  dimensional transducers  that can better  quantify the  complex  motion  of the thumb.  Despite  these 
advances,  the use of AMG can  be limited  due to  patient  positioning that  precludes  free motion of 
the thumb, as  well  instances  of awakening  patients  moving their  thumb during measurements.   
Kinemyography (KMG)  is based  on similar  principles to  AMG, and  relies  on the thumb being 
able to  move freely.   Upon  neurostimulation, KMG utilizes  a piezoelectric  motion  sensor that  is 
bent between  the thumb and  index fingers  following muscle  contraction.  The  degree  of this  
bending is  quantified and used  to determine  a TOF  ratio.   While  Datex -Ohmeda (Helsinki,  
Finland) manufactures  a KMG device that  can be incorporated into  the anesthesia work  station,  
there are  no currently  available  standalone KMG devices.   Electromyography (EMG) devices  
measure electrical  activity,  termed  compound muscle  action  potentials  (cMAPs)  following nerve 
stimulation  (typically  at the adductor pollicis  muscle  after  ulnar nerve stimulation).   As EMG  
measures  cMAPs  and does  not require  freely  moving thumbs for accurate measurements,  many  
experts  have referred  to this monitoring modality  as the “new  gold standard”.  TetraGraph  
(Senzime  AB,  Uppsala,  Sweden)  is a standalone EMG -based  device that  recently  received  
Conformité Européene (CE)  approval.    We  have  pre viously investigated  this device and  
presented  our findings at several  annual meetings  such as International  Anesthesia Research  
Society  (May  2018, May  2017, May  2013), the Society  for Technology in  Anesthesia (January  
2018), and  the American  Society  of Anesthesiologists (Octotober 2017, October  2012), 
European Society  of Anaesthesiology (June 2018, June 2015).  Furthermore, we  have recently  
submitted  abstracts  to the PostGraduate Assembly  in Anesthesiology in  December  2018 as  well  
as a manuscrip t describing  a multi- center,  volunteer study investigating  TetraGraph  versus 
AMG- based  monitors.  Our work  thus far has  found this  device to  be easy  to apply, reliable,  and 
able to  provide comparable measurements  to other quantitative  monitors.   
Utilizing  recommendations  from  the  Good Clinical Practice (GCP) Guidelines for monitoring of  
neuromuscular function (Fuchs-Buder et  al. 2007), we  will investigate  the performance of  the 
TetraGraph  in patients  recovering  from  anesthesia  in the PACU.   The  postoperative setting  is 
particularly  important,  as several  previous studies performed  in awakening  patients  have reported  
discordant TOF  ratios: accelerographic TOF  ratios  were not an  accurate representation  of the 
neuromuscular status  (recovery)  of the patients  (Baillard  et al. 2004). We  plan  to compare two  
portable quantitative  monitors,  the EMG -based  TetraGraph  and the AMG- based  ToFscan.   
ToFscan  has recently  been  described  as an acceptabl e surrogate  for research  purposes to  the 
frequently used  TOF -Watch  (Murphy  et al. 2018).  The  TOF -Watch  monitor, however, is  no 
longer manufactured, while  the ToFscan  is commercially  available and  approved by  the United  
States  Food and  Drug  Administration  (FDA).   While  the ToFscan  has a three -dimensional sensor 
that can measure acceleration  in multiple  planes,  it still has  the same limitations  associated  with 
muscle  movement inherent to  AMG- based  quantitative monitors.  This  is of particular  
importance in  the recovery  room when  patients  may  not be  fully  cooperative when  quantitative  
monitoring is  warranted  to exclude postoperative residual  weakness  as a cause of patient  distr ess. 
 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 10 of 30 
J. Ross Renew , MD   CONFIDENTIAL  4.3 Risk s and Benefits  
 
• The benefits of using neuromuscular blockade monitoring devices:  
Early detection of residual neuromuscular blockade 
• The risks of using neuromuscular blockade monitoring devices: Slight discomfort when electrical stimulation is administered  
 Study Objectives  5
 
Primary Objective  
To assess the agreement and repeatability between TOF values obtained from the ToFscan and TetraGraph  during recovery from neuromuscular blockade as measured upon arrival to the 
PACU, and then  5 (+5 min) and 10 (+10 min)) minutes later.  Secondary Objective  
Determine the incidence of postoperative residual weakness in the PACU (defined as TOFR <0.90). Assess patient discomfort associated with each neurostimulation utilizing a verbal numeric rating scale (VNRS) from 0 -10.   
 
 Study Design  6
 
6.1 General Description  
 
This unblinded, multicenter  international , prospective, randomized, observational study will 
involve 120 patients undergoing surgical procedure that involved administration of 
neuromuscular blockade agents intraoperatively.   
6.2 Number of Subjects  
 
One hundred twenty ( forty per site).  
6.3 Duration of Participation  
 
10 minutes in PACU  
     
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 12 of 30 
J. Ross Renew , MD   CONFIDENTIAL   Subject Selection Enrollment and Withdrawal  7
7.1 Inclusion Criteria  
 
• Age > or = 18 years old 
• Patients willing to participate and provide an informed consent 
• Patients undergoing an elective surgical procedure that requires use of non-depolarizing 
NMBA agents administered intraoperatively. 
7.2 Exclusion Criteria  
 
• Patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken wrist 
with nerve damage, Dupuytren contracture , or any similar wrist injury.   
• Patients  with systemic neuromuscular diseases such as myasthenia gravis  
• Patients with significant organ dysfunction that can significantly affect pharmacokinetics of neuromuscular blocking and reversal agents, i.e., severe renal impairment or end- stage 
liver disea se. 
 
7.3 Subject Recruitment, Enrollment  and Screening  
 
Subjects will be enrolled from the Departments of Anesthesiology at the Mayo Clinic in Florida , 
NorthShore University Health System, and University of Debrecen. The study has an accrual 
target of 120 patients. On a daily basis, there are over 20 elective surgical cases performed at 
Mayo Clinic in Florida  and thus no difficulties in accrual based on historical volumes are 
anticipated.  Each participating center reviewed the feasibility and determined that approximately 
3 participants per week will be completed for this study.  The initial accrual period will last  at 
least 3 months. Patients will be provided with a Research Participant Consent and Privacy 
Authorization Form describing the study devices , pro tocol, inclusion and exclusion criteria, as 
well as risks and benefits of participation.  
7.4 Early Withdrawal of Subjects 
7.4.1 When and How to Withdraw Subjects  
 
Patients are free to withdraw at any time and for whatever reason.  If patient withdraws consent 
prior to arrival to PACU, the study data will not be collected. If patient withdraws consent after 
study data was already completed, the participant will need to provide instructions to the study 
team to remove his/her data from the data set.  Pre-specified reasons for discontinuing include, 
but are not limited to, the following:  
• Patient Request: Patient decided that he/she did not want to continue (for any reason) 
• Adverse Event: Patient experienced a related or unrelated even t that would interfere with 
the study objectives/evaluation  
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 13 of 30 
J. Ross Renew , MD   CONFIDENTIAL  • Inclusion/Exclusion Discrepancy/Violation: Patient should not have been enrolled 
• Other: Any other reason  
 
7.4.2 Data Collection and Follow- up for Withdrawn Subjects  
 
If a Participant withdraws from the  study, no additional attempts will be made to contact the 
Participant.  
 Study D evice   8
8.1 Description  
 
ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes  (Murphy et al, 2018).  
 TetraGraph device is a neuromuscular transmission monitor capable of estimating th e depth of 
neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation.   
8.2 Method for Assigning Subjects to Treatment Groups  
 
This is an open- label pilot investigation and all study participants are assigned to both standard 
of care and investigational device use in PACU. The randomization involves the use of dominant 
vs non-dominant arm.  The randomization will be performed utilizing REDCap and assigned anesthesia clinical care team will be informed of patients’ assigned to guide them with the selection of the assigned 
treatment option.  
 
8.3 Masking/ Blinding of Study  
 
This is an open- label pilot investigation. Masking and blinding procedures are not applicable.   
 
 Study Procedures  9
 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 14 of 30 
J. Ross Renew , MD   CONFIDENTIAL  9.1 Visit 1  (Screening and Enrollment  up to the day of surgery) 
 
• Review of medical record  
• Informed Consent - Patients will be identified  during their preoperative appointment and 
introduced to a study; they will be provided with a copy of the consent document and 
information about the study. The consenting will take place after additional discussion on the day of surgery.   
9.2 Visit 2  (Random ization and Treatment  – day of surgery) 
 
• Elective surgical procedure as per standard of care  
• Intraoperative neuromuscular blockade, management, and neuromuscular antagonism 
will be at the discretion of the attending anesthesiologist.  
• Upon arrival to the PACU, consenting patients will be randomized to have the 
TetraGraph placed on either their dominant or non-dominant arm TetraGraph uses proprietary, single- use surface electrodes (TetraSens
TM, Senzime AB, Uppsala, Sweden) 
with stimulating electrodes placed over the ulnar nerve, a reference electrode placed on the adductor pollicis  (1st digit) ( Figure 16.1
).  The skin will be prepped with careful 
abrasion and cleansing of the skin in the usual fashion prior to electrode placement.  
• ToFscan will be placed on the patient’s opposite arm.  Stimulating electrodes (Red Dot 
ECG electrodes, 3M, St. Paul, MN) will be placed over the ulnar nerve with the negative 
electrode near the wrist crease and positive electrode placed 3 -4 cm proximally.  The skin 
will be prepped with careful abrasion and cleansing of the skin in the usual fashion prior to electrode placement. The ToFscan utilizes a thumb splint with the encased transducer secured to the hand ( Figure 16.2
).  
• To obtain measurements with TetraGraph, TOF stimulation will be performed at 50mA 
and the measurement recorded. This measurement will be repeated twice, 20 seconds 
apart.  If the two measurements differ by >10%, a third measurement will be recorded, with the closest two readings kept and the outlier discarded.  If TetraGraph yields a train-of-four count but not a ratio with any measurement, this will be recorded.  
• To obtain ToFscan measurements, TOF stimulation will be performed and the 
measurement recorded.  According to the manufacturer, the ToFscan does not require 
calibration, and the default stimulating current is 50 mA.  The TOF measurement will be repeated twice, 20 seconds apart. If the measurements di ffer by >10%, a third 
measurement will be repeated, with the closest two readings kept and the outlier discarded.  If TetraGraph yields a train -of-four count but not a ratio with any 
measurement, this will be recorded.  
• Each  neurostimulation with the Tetra Graph  and ToF scan will be conducted 
simultaneously with two observers. Patients  will be queried as to the level of discomfort 
associated with obtaining measurements ( Figure 16.3
).  We have previously utilized this 
scoring system for a large, multi- center volunteer trial (manuscript submitted). If patients 
are unable to quantify their discomfort, this will be documented. 
• The above described  process will be repeated for both monitors upon arrival to PACU 
and after 5 minutes and 10 min utes into the PACU stay.  
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 15 of 30 
J. Ross Renew , MD   CONFIDENTIAL  • ToFscan is an FDA approved monitor, while TetraGraph is CE marked, but not FDA 
approved yet. If TOF ratios below 0.9 are obtained with the ToFscan at any point during 
this study, the attending anesthesiologist will be notified, as  per usual clinical routine.  
Possible actions include continued monitoring and supportive care, additional reversal agent administration, or, in extreme cases of weakness, ventilatory support with bilevel positive airway pressure (BiPAP) or tracheal re -intubation. 
• Following measurements obtained with both devices at these specified time intervals and 
assuming TOF ratio is >0.9, the devices will be removed and the patient will proceed 
along the standard recovery pathway.  
• If at any point the patient describes the discomfort associated with neurostimulation as a 
verbal numeric score of 7 or higher, the patient will be given the option to discontinue the 
study.  
• Prior to discharge from PACU, patients will be asked to recall if they had a neurostimulation. If th ey do recall it, we will again query the level of discomfort 
associated with obtaining measurements ( Figure 16.3
). 
 
9.3 Schedule of Events  
 
 
Schedule of Events  
Study Activity  Visit  1  Visit 2 
ToFscan and 
Tetragraph   X 
Informed consent  X  
Review of Medical 
Record  X  
Adverse  event 
evaluation   X 
 
 Statistical Plan  10
10.1 Sample Size Determination  
 
Based  on paired  t-test, 23 enrolled  patients  will give  90% power to  detect  a difference in  TOF  
ratios  with  a significance  level  of 0.05 (JMP  Pro Software  version  13.0.0 [August 23, 2018]; 
SAS Institute  Inc., Cary,  NC).  We utilized  a standard  deviation of  0.07 that was  determined  
during our multi- center  volunteer study comparing  another AMG device and TetraGraph.   
However,  we will enroll 40 patients  at 3 sites  for a total of 120 patients  to account  for dropout 
during the study and  to provide further insight into  the incidence of  postoperative residual  
weakness  and three  large  centers.   The  other centers  that might be submitting  similar  studies and  
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 16 of 30 
J. Ross Renew , MD   CONFIDENTIAL  sharing de -identified  data  for the purposes of  data analysis  and publication are as  follows: 
NorthShore Universi ty HealthSystem,  Evanston, IL, USA  
 and University of  Debrecen,  Debrecen,  
Hungary . Each  
site will complete  separate applications for their  IRB or Ethics  committee  approval; Mayo  Clinic  
in Florida will serve as the lead  site and will provide oversight to  ensure compliance with  the 
protocol at  each  site.  .  
 
10.2 Statistical Methods  
 
Descriptive Statistics  
 
Analysis  of agreement  between  the devices  will be assessed  using the method  described  by 
Bland  and Altman  (Olofsen  et al. 2015).  The  bias is defined  as the mean  difference of  repeated  
measurements  from  the ToFscan  and the TetraGraph  obtained at  the same time intervals.  The 
limits  of agreement  are defined  as bias ± 2 SD,  where SD  denotes the standard  deviations of the 
differences.   Limits  of agreement  are interpreted  as the reference range  within  which  95% of the 
differences  will lie.   The  bias and the limits  of agreements  surrounding the bias (± 2 SD)  will be 
calculated  with 95% confidence intervals.   Repeatability  between  the two  devices  at the various 
time intervals  will also  be assessed  with  significance defined  as a p-value <0.05.  
 
Handling of Missing Data 
 
This is a prospective study and therefore we do not anticipate any missing data.  In the event of 
any unexpected missing data, no attempt to impute this missing data will be made; missing data 
will simply be treated as missing in the statistical analysis.  
 
10.3 Subject Population(s) for Analysis  
 
Each participant who goes through the recovery processes in the PACU and completes 
monitoring of residual neuromuscular blockade will be included in the primary analysis regardless of study withdrawal for any reason. In the event of any study withdrawals, in secondary analysis we will examine the sensitivity of our results to the exclusion of patients who 
withdrew.  

ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 17 of 30 
J. Ross Renew , MD   CONFIDENTIAL   Safety and Adverse Events  11
11.1 Definitions  
11.1.1  Unanticipated Problems Involving Risk to  Subjects or Others (UPIRTSO)  
Any unanticipated problem or adverse event that meets the following three criteria:  
• Serious : Serious problems or events that results in significant harm, (which may be 
physical, psychological, financial, social, economic, or legal) or increased risk for the 
subject or others (including individuals who are not research subjects). These include: (1) death; (2) life threatening adverse experience; (3) hospitalization - inpatient, new, or prolonged; (4) disability/incapacity - per sistent or significant; (5) birth defect/anomaly; (6) 
breach of confidentiality and (7) other problems, events, or new information (i.e. publications, DSMB reports, interim findings, product labeling change) that in the opinion of the local investigator ma y adversely affect the rights, safety, or welfare of the subjects 
or others, or substantially compromise the research data, AND  
• Unanticipated: (i.e. unexpected) problems or events are those that are not already 
described as potential risks in the protocol, consent document, or not part of an underlying disease. A problem or event is "unanticipated" when it was unforeseeable at the time of its occurrence. A problem or event is "unanticipated" when it occurs at an increased frequency or at an increased severi ty than expected, AND 
• Related: A problem or event is "related" if it is possibly related to the research procedures.  
  
11.1.2  Adverse Event  
An untoward or undesirable experience associated with the use of a medical product (i.e. drug, device, biologic) in a patient or research subject.  
11.1.3  Serious Adverse Event  
Adverse events are classified as serious or non -serious.  Serious problems/events can be well 
defined and include; 
• death  
• life threatening adverse experience  
• hospitalization  
• inpatient, new, or prolonged; disability/incapacity  
• persistent or significant disability or incapacity  
• birth defect/anomaly  
 and/or per protocol may be problems/events that in the opinion of the sponsor-investigator may have adversely affected the rights, safety, or welfare of the subjects or others, or substantially compromised the research data.  
  All adverse events that do not meet any of the criteria for serious , should be regarded as non-
serious adverse events .  
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 18 of 30 
J. Ross Renew , MD   CONFIDENTIAL   
11.1.4  Adverse Event Reporting Period  
 
For this study, the follow-up period is defined as 10  minutes following the arrival in the PACU.  
 
11.1.5  Preexisting Condition  
A preexisting condition is one that is present at the start of the study.  A preexisting condition should be recorded as an adverse event if the frequency, intensity, or the character of the condition worsens during the study period.  
 
11.1.6  Post -study Adverse Event  
All unresolved adverse events should be followed by the sponsor-investigator until the events are 
resolved, the subject is lost to follow-up, or the adverse event is otherwise explained.  At the last scheduled visit, the sponsor-investigator should instruct each subject to report, to the sponsor-investigator, any subsequent event(s) that the subject, or the subject’s personal physician, believes might reasonably be related to participation in this study.   
  
11.1.7  Hospitalization, Prolonged Hospitalization or Surgery  
Any adverse event that results in hospitalization or prolonged hospitalization should be documented and reported as a serious adverse event unless specifically instructed otherwise in this protocol.  Any condition responsible for surgery should be documented as an adverse event if the condition meets the criteria for an adverse event.   
 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an 
adverse event in the following circumstances:   
• Hospitalization or prolonged hospitalization for therapy of the target disease of the study, unless it is a wor sening or increase in frequency of hospital admissions as judged by the 
clinical investigator.  
 
11.2 Recording of Adverse Events  
At each contact with the subject, the study team must seek information on adverse events by 
specific questioning and, as appropriate, by examination.  Information on all adverse events should be recorded immediately in the source document, and also in the appropriate adverse event section  of the electronic case report form (CRF). All clearly related signs, symptoms, and 
abnormal diagnostic , laboratory or procedure results should recorded in the source document. 
 All adverse events occurring during the study period must be recorded.  The clinical course of each event should be followed until resolution, stabilization, or until it has been ultimately determined that the study treatment or participation is not the  probable cause.  Serious adverse 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 19 of 30 
J. Ross Renew , MD   CONFIDENTIAL  events that are still ongoing at the end of the study period must be followed up, to determine the 
final outcome.  Any serious adverse event that occurs during the Adverse Event Reporting Period  and is considered to be at least possibly related to the study treatment or study 
participation should be recorded and reported immediately. 
11.3 Reporting of Serious Adverse Events and Unanticipated Problems  
 
When an adverse event has been identified, the study team will take appropriated action necessary to protect the study participant and then co mplete the Study Adverse Event Worksheet 
and log.  The sponsor- investigator will evaluate the event and determine the necessary follow -up 
and reporting required.  
11.3.1 Sponsor -Investigator reporting: notifying the Mayo IRB   
 
The sponsor-investigator will report to the Mayo IRB any UPIRTSOs and Non- UPIRTSOs 
according to the Mayo IRB Policy and Procedures. Each participating  site will report SAEs to 
their respective IRB or Ethics Committee with copy of submission and review provided to the leading site. Should there be any SAEs at any of the participating sites;  the study team at that site 
will notify the primary site (Mayo C linic in Florida) within 24 hours of learning of the event.  
 Any serious adverse event (SAE) which the Principal Investigator has determined to be a 
UPIRTSO will be reported to the Mayo IRB as soon as possible but no later than 5 working days  
after the investigator first learns of the problem/event.  The following i nformation will be collected on the adverse event worksheet (and entered in the 
research database):  
• Study ID  
• Disease  
• The date the adverse event occurred  
• Description of the adverse event  
• Relationship of the adverse event to the researc h device*  
• Determination if the adverse event was expected   
• The severity of the adverse event ( severity scale described below **) 
• If any intervention  was necessary  
• Resolution (was the incident resolved spontaneously, or after discontinuing treatment) 
• Date of Resolution 
 
The sponsor- investigator will review all adverse event reports to determine if specific reports 
need to be made to the IRB .  The sponsor- investigator will sign  and date the adverse event report 
when it is reviewed.  For this protocol, only directly related SAEs /UPIRTSO s will be reported to 
the IRB.  
  
* Relationship Index  
 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 20 of 30 
J. Ross Renew , MD   CONFIDENTIAL  The relationship of an AE to the Investigational  Device is a clinical decision by the sponsor-
investigator (PI) based on all available information at the time of the completion of the eCRF and 
is graded as follows:  
 1. Not related: a reaction for which sufficient information exists to indicate that the etiolog y is 
unrelated to the use and proper application of study d evice.  
 2. Unlikely : a clinical event, including laboratory test abnormality, with a temporal relationship 
to use of the study device which makes a causal relationship improbable and in which use o f 
other devices , chemicals, or underlying disease provide plausible explanations. 
 3. Possible: a clinical event, including laboratory test abnormality, with a reasonable time sequence to use of the study device but which could also be explained by concurr ent disease or 
use of other devices  or chemicals . 
 4. Probable: a clinical event including laboratory test abnormality, with a reasonable time sequence to use of the study device, unlikely to be attributed to concurrent disease or use of other devices  or chemicals . 
 5. Definite: a reaction that follows a reasonable temporal sequence from the use of the study device.  
  
** Severity Scale  
 
The maximum intensity of an AE during a day should be graded according to the definitions 
below and recorded in details as indicated on the CRF. If the intensity of an AE changes over a number of days, then separate entries should be made having distinct onset dates.  
 1. Mild: AEs are usually transient, requiring no special treatment, and do not interfere with patient’s  daily activities.  
 2. Moderate: AEs typically introduce a low level of inconvenience or concern to the patient and may interfere with dail y activities, but are usually ameliorated by simple therapeutic measures.  
 3. Severe: AEs interrupt a patient's usual daily activity and traditionally require  systemic drug 
therapy or other treatment.  
 
11.4 Medical Monitoring  
It is the responsibility of the Principal Investigator (at each participating site) to oversee the 
safety of the study at his/her site.  This safety monitoring will include careful assessment and 
appropriate reporting of adverse events as noted above, as well as the construction and impleme ntation of a site data and safety -monitoring plan (see section 10  “Study Monitoring, 
Auditing, and Inspecting”).  Medical monitoring will include a regular assessment of the number and type of serious adverse events. 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 21 of 30 
J. Ross Renew , MD   CONFIDENTIAL   
 Data Handling and Record Keeping  12
12.1 Confidentiality  
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a signed subject authorization infor ming the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the ability to use all information collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to coll ect at least vital status (long term survival status that 
the subject is alive) at the end of their scheduled study period. 
12.2 Source Documents  
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contai ned in source documents.  Examples of these original documents, and data records 
include: hospital records and any forms completed specifically for this study.  
12.3 Case Report Forms  
 
All data necessary for this study will be obtained from EHR  or at the time d evices are being used  
and recorded on the electronic Case Report Forms (CRFs) created in REDCap. All missing data will be explained.   
12.4 Data Management 
 
Study data to be collected and managed using EHR and study -generated source documents  and 
transcribed into electronic CRFs in REDCap , electronic data capture software, hosted by CTSA 
at Mayo Clinic.  REDCap (Research Electronic Data Capture) is a secure, web -based application 
designed to support data capture for research studies, providing  1) an intuitive interface for 
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) 
automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources.  
 
Each center will enter data into Mayo Clinic developed REDCap database. The administrator for 
REDCap added external users with their unique username and Data Access Groups (DAGs) were 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 22 of 30 
J. Ross Renew , MD   CONFIDENTIAL  created to ensure centers were only able to access th eir own data. Mayo Clinic Florida will have 
access to the entire de -identified data set.  
 
Each center is designated a site number and the following naming convention for the records will 
be used: 01-XXX – First two digits for site number and last three digits sequential subject files (starting at 
001). Mayo Clinic Florida will use the following format for their subject files: 01- 001, 01-002, 
etc. 
See Table with the list of participating centers and site number to identify correct naming conventions for the subject files.  
 
12.5 Data Processing 
 
All study date will be stored and analyzed at Mayo Clinic in Florida using the REDC ap 
electronic data capture tool. De-identified data will be shared with investigators conducting 
similar study at their institution for the  purposes of combined data analysis and publication. 
 
Study center at NorthShore will not be entering any PHI in REDCap, specifically the date of birth and date of surgery will not be entered by this center into REDCap. A free -text to enter age 
will be the designated field for the NorthShore center to enter. 
 
12.6 Data Security and Confidentiality  
 
All source documents including clinical findings, observations or other activities will be stored in a REDCap  database that will be designed by an Investigator .  Access to the REDCap database 
will be limited to the Principal Investigator, Investigators, Study Team members, and Statistician.  
 
12.7 Data Quality Assurance 
 
Once the study is completed the Principal Invest igator will randomly select 3 participants and 
compare the data documented in the EHR with what is entered into the REDCap database.  If 
there is any discrepancy, the Principal Investigator and/or Investigators will cross -reference all 
30 patients to ensur e accuracy.  
 Participating centers will be asked to provide de -identified/redacted source documents for 
selected subjects for verification of data.  
 
12.8 Data Clarification Process 
 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 23 of 30 
J. Ross Renew , MD   CONFIDENTIAL  For any data query the Principal Investigator and Investigators will meet to clarify the data 
queried and make corrections based on consensus.  
12.9 Records Retention  
 
The sponsor- investigator will maintain records and essential documents related to the conduct of 
the study.  These will include subject case histories and regulatory documents. Each site’s 
Principal Investigator will maintain regulatory and essential study documents to ensure compliance with local and federal policies/guidelines.   
The sponsor-i nvestigator will retain the s pecified records and reports:  
1. As outlined in the Mayo Clinic Research Policy Manual –“Retention of and Access to 
Research Data Policy” http://mayocontent.ma yo.edu/research -policy/MSS 669717
   
 
 Study Monitoring, Auditing, and Inspecting  13
13.1 Study Monitoring Plan 
 
The investigator will allocate adequate time for such monitoring activities.  The Investigator will 
also ensure that the compliance or quality assurance reviewer is given access to all the study -
related documents . 
 
13.2 Auditing and Inspecting  
The investigator will permit study -related monitoring, audits, and inspections by the IRB, the 
sponsor, and government regulatory agencies, of a ll study related documents  (e.g. source 
documents, regulatory documents, data collection instruments, study data etc.).   
 Participation as an investigator in this study implies acceptance of potential inspection by government regulatory authorities and applicable compliance offices.  
 Ethical Considerations  14
This study is to be conducted according to U nited States  and International government 
regulations and Institutional research policies and procedures.  This protocol and any amendments will be submitted to a properly constituted lo cal Institutional 
Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the 
study.  The decision of the IRB concerning the conduct of the study will be made in writing to 
the sponsor- investigator before commencement of this study.  
 All subjects for this study will be provided a consent form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study.  This consent form will be submitted with  the protocol for review and approval by the IRB 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 24 of 30 
J. Ross Renew , MD   CONFIDENTIAL  for the study.  The formal consent of a subject, using the Approved IRB consent form, must be 
obtained before that subject undergoes any study procedure.  The consent form must be signed by the subject and t he individual obtaining the informed consent. 
 
 Study Finances  15
15.1 Funding Source  
 This investigator initiated study is not funded. Study coordinator’s time is supported by the Department of Anesthesiology.  
15.2 Conflict of Interest  
 
Any study team member  who has a conflict of interest with this study (patent ownership, 
royalties, or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by a properly constituted Conflict of Interest Committee with a Committee -sanctioned conflict management plan that has been reviewed and approved by the 
study sponsor-investigator prior to participation in this study. 
 
No financial conflicts of interested are anticipated or have been identified for this study. 
15.3 Subject Stipends or Payments  
 
No payment is given to study participants.  
 
 Publication Plan  16
 The primary responsibility for publication of the study results is with the Primary Investigator. 
After the complication of study and prior to publication, the study results  will be shared with all 
Investigators . The study will be registered  at ClinicalTrials.gov prior to subject recruitment along 
with the posting of the results within 12 months of final data collection for the primary outcome  
measure.  
 
 Referen ces 17
 
 
Baillard, C., S. Bourdiau, P. Le Toumelin, F. Ait Kaci, B. Riou, M. Cupa, and C. M. Samama. 2004. 
'Assessing residual neuromuscular blockade using acceleromyography can be deceptive in 
postoperative awake patients', Anesth Analg, 98: 854- 7, table of contents.  
Berg, H., J. Roed, J. Viby -Mogensen, C. R. Mortensen, J. Engbaek, L. T. Skovgaard, and J. J. Krintel. 
1997. 'Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 25 of 30 
J. Ross Renew , MD   CONFIDENTIAL  prospective, randomised, and blinded study of postoperative pulmonary complications after 
atracurium, vecuronium and pancuronium', Acta Anaesthesiol Scand, 41: 1095- 103. 
Cammu, G., J. De Witte, J. De Veylder, G. Byttebier, D. Vandeput, L. Foubert, G. Vandenbroucke, and T. 
Deloof. 2006. 'Postoperative residual paralysis in outpatients versus inpatients', Anesth Analg, 
102: 426- 9. 
Elyassi, A. R., and H. H. Rowshan. 2009. 'Perioperative management of the glucose-6- phosphate 
dehydrogenase deficient patient: a review of literature', Anesth Prog, 56: 86- 91. 
Erikss on, L. I., E. Sundman, R. Olsson, L. Nilsson, H. Witt, O. Ekberg, and R. Kuylenstierna. 1997. 
'Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers', 
Anesthesiology , 87: 1035- 43. 
Evora, P. R., L. Alves Junior, C. A. Ferreira, A. C. Menardi, S. Bassetto, A. J. Rodrigues, A. Scorzoni 
Filho, and W. V. Vicente. 2015. 'Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised', Rev Bras Cir Cardiovasc , 30: 84- 92. 
Faber, P., A. Ronald, and B. W. Millar. 2005. 'Methylthioninium chloride: pharmacology and clinical 
applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypas s', Anaesthesia, 60: 575- 87. 
Fuchs -Buder, T., C. Claudius, L. T. Skovgaard, L. I. Eriksson, R. K. Mirakhur, J. Viby -Mogensen, and 
Meeting th International Neuromuscular. 2007. 'Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision', Acta 
Anaesthesiol Scand, 51: 789 -808. 
Grayling, M., and B. P. Sweeney. 2007. 'Recovery from neuromuscular blockade: a survey of practice', 
Anaesthesia, 62: 806- 9. 
Kaisers, U., J. M. Langrehr, M. Haack, A. Mohnhaupt, P. Neuhaus, and R. Rossaint. 1995. 'Hepatic 
venous catheterization in patients undergoing positive end- expiratory pressure ventilation after 
OLT: technique and clinical impact', Clin Transplant , 9: 301-6. 
McCartney, S. L., L. Duce, and K. Ghadimi. 2018. 'Intraoperative vasoplegia: methylene blue to the 
rescue!', Curr Opin Anaesthesiol , 31: 43 -49. 
Murphy, G. S., J. W. Szokol, M. J. Avram, S. B. Greenberg, J. H. Marymont, J. S. Vender, J. Gray, E. 
Landry, and D. K. Gupta. 2011. 'Intraoperative acceleromyography monitoring reduces symptoms 
of muscle weakness and improves quality of recovery in the early postoperative period', 
Anesthesiology , 115: 946- 54. 
Murphy, G. S., J. W. Szokol, M. J. Avram, S. B. Greenberg, T. D. Shear, M. Deshur, J. Benson, R. L. 
Newmark, and C. E. Maher. 2018. 'Comparison of the TOFscan and the TOF -Watch SX during 
Recovery of Neuromuscular Function', Anesthesiology . 
Murphy, G. S., J. W. Szokol, M. J. Avram, S. B. Greenberg, T. D. Shear, J. S. Vender, K. N. Parikh, S. S. 
Patel, and A. Patel. 2015. 'Residual Neuromuscular Block in the Elderly: Incidence and Clinical Implications', Anesthesiology , 123: 1322- 36. 
Murphy, G. S., J. W. Szokol, J. H. Marymont, S. B. Greenberg, M. J. Avram, and J . S. Vender. 2008. 
'Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit', Anesth Analg, 107: 130- 7. 
Naguib, M., S. J. Brull, A. F. Kopman, J. M. Hunter, B. Fulesdi, H. R. Arkes, A. Elstein, M. M. Todd, and 
K. B. Johnson. 2018. 'Consensus Statement on Perioperative Use of Neuromuscular Monitoring', 
Anesth Analg, 127: 71- 80. 
Naguib, M., A. F. Kopman, and J. E. Ensor. 2007. 'Neuromuscular monitoring and postoperative residual 
curarisation: a meta- analysis', Br J Anae sth, 98: 302- 16. 
Naguib, M., A. F. Kopman, C. A. Lien, J. M. Hunter, A. Lopez, and S. J. Brull. 2010. 'A survey of current 
management of neuromuscular block in the United States and Europe', Anesth Analg, 111: 110-
9. 
Olofsen, E., A. Dahan, G. Borsboom, and G. Drummond. 2015. 'Improvements in the application and 
reporting of advanced Bland- Altman methods of comparison', J Clin Monit Comput , 29: 127- 39. 
Sundman, E., H. Witt, R. Olsson, O. Ekberg, R. Kuylenstierna, and L. I. Eriksson. 2000. 'The incidence 
and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: 
pharyngeal videoradiography and simultaneous manometry after atracurium', Anesthesiology , 92: 
977-84. 
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 26 of 30 
J. Ross Renew , MD   CONFIDENTIAL  Todd, M. M., and B. J. Hindman. 2015. 'The Implementation of Quan titative Electromyographic 
Neuromuscular Monitoring in an Academic Anesthesia Department: Follow -Up Observations', 
Anesth Analg, 121: 836- 8. 
Todd, M. M., B. J. Hindman, and B. J. King. 2014. 'The implementation of quantitative electromyographic 
neuromuscul ar monitoring in an academic anesthesia department', Anesth Analg, 119: 323- 31. 
Woehlck, H. J., B. T. Boettcher, K. K. Lauer, D. C. Cronin, J. C. Hong, M. A. Zimmerman, J. Kim, and M. 
Selim. 2016. 'Hydroxocobalamin for Vasoplegic Syndrome in Liver Transplantation: Restoration 
of Blood Pressure Without Vasospasm', A A Case Rep , 7: 247- 50. 
  
 List of In-Text Tables  18
18.1 Schedule of Events  
 
 
Schedule of Events  
Study Activity  Visit  1  Visit 2 
ToFscan and 
Tetragraph   X 
Informed consent  X  
Review of Medical 
Record  X  
Adverse  event 
evaluation   X 
 
18.2 Intraoperative Data  
 
Study  ID:  
Examiner  
Initials:   Date  (dd / mm / 
yyyy):   
 
Muscle  relaxant  name:   
Muscle  relaxant  total dose (mg):   
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 27 of 30 
J. Ross Renew , MD   CONFIDENTIAL  Time  of last muscle  relaxant  dose (mm  : hh):                             :                        am  /  pm 
 
Reversal  agent  name:   
Reversal  agent  dose (mg):   
Time  of reversal  agent  administration  (mm  : hh):                         :                   am  /  pm 
 
Time  of extubation:                                 :                               am  /  pm 
 
TOF  ratio / TOF  count  at the time of reversal  (if available):  
Monitor  used 
during reversal:  PNS  /  IntelliVue  NMT   /  ToFscan   /  None  
Site of monitoring  
during reversal:  Hand   /  Face   /  Leg 
 
TOF  ratio / TOF  count  at the time of extubation  (if available):  
Monitor  used at 
extubation:  PNS  /  IntelliVue  NMT   /  ToFscan   /  None  
Site of monitoring:  Hand   /  Face   /  Leg 
 
18.3 PACU data  
 
Study  ID   
Date  of Surgery  (dd / mm / yyyy ):  
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 28 of 30 
J. Ross Renew , MD   CONFIDENTIAL  Initials:   Dominant  side:  L  /  R Age (yrs):   
Weight  (kg):   Height  (cm):   BMI:   
 
TetraGraph  (TG)     Arm tested:    dominant / non-dominant  
 TOFR  #1 TOFR  #2 TOFR  #3 
(if needed)  VNRS   
T0 (on arrival  to 
PACU)      
T5 (5 min later)      
T10 (10 min later)      
Predischarge  
VNRS  xxx xxx xxx  
 
ToFscan (TS)   Arm tested:     dominant / non-dominant 
 TOFR  #1 TOFR  #2 TOFR  #3 
(if needed)  VNRS   
T0 (on arrival  to 
PACU)      
T5 (5 min later)      
T10 (10 min later)      
Predischarge  
VNRS  xxx xxx xxx  
TG=  TetraGraph;  TS=  ToFscan;  TOFR=  train -of-four ratio; VNRS=  verbal numeric rating  scale  
ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 29 of 30 
J. Ross Renew , MD   CONFIDENTIAL   
 List of In-Text Figures 19
19.1 TetraGraph  
 
 
19.2 ToFscan 
 

ToFscan vs TetraGraph   Version 3.0 
  11/Oct/19  
Page 30 of 30 
J. Ross Renew , MD   CONFIDENTIAL  19.3 VNRS  
 
